Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150510 | 0.86 | MAPT (0.53) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL686650 | 0.84 | MAPT (0.58) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL6700367 | 0.84 | LMNA (0.55) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL15869752 | 0.82 | MAPT (0.56) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL14228414 | 0.82 | MAPT (0.56) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL3197041 | 0.81 | APP (0.50) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL11163647 | 0.81 | LMNA (0.55) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL11857933 | 0.81 | CYP19A1 (0.57) | MAPTTDP1L3MBTL1MAPK1MAOB | |
| SCHEMBL2096058 | 0.81 | LMNA (0.61) | MAPTL3MBTL1MAOBMCL1SMN1; SMN2 | |
| SCHEMBL9376228 | 0.80 | PTGER1 (0.50) | MAPTTDP1L3MBTL1MAPK1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9366906-B2 | Photoreactive compounds | ROLIC AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20140192305-A1 | PHOTOREACTIVE COMPOUNDS | ROLIC AG (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0622393-B1 | Modified aromatic polycarbonate resin and modified phenol for preparing it | TEIJIN CHEMICALS LTD (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5463013-A | Transparency, heat resistance, dimensional stability, tracking resistance | TEIJIN CHEMICALS, LTD. (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0622393-A2 | Modified aromatic polycarbonate resin and modified phenol for preparing it | Teijin Chemicals, Ltd. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0525888-A1 | New catechol type non-steroidal drugs as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MAPT 3268/4885TDP1 4280/4885L3MBTL1 3894/4885 |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MAPT 3268/4885TDP1 4280/4885L3MBTL1 3894/4885 |
| US-20140192305-A1 | PHOTOREACTIVE COMPOUNDS | PCNA, CRY1, CRY2 | MAPT 124/4885TDP1 1806/4885L3MBTL1 1772/4885 |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MAPT 3268/4885TDP1 4280/4885L3MBTL1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.